Resources

Microarray patch (MAP) technologies can address the need for improved presentations of vaccines. The PATH Center of Excellence for MAP Technology is advancing MAP development for high priority needs in low- and middle-income countries (LMICs). The development of a vaccine MAP depends on a number of technical, clinical, regulatory, and commercialization factors. To aid in selecting an appropriate antigen, this document overviews key antigen qualities that impact the likelihood of successful technical development for a vaccine MAP.

This document is a resource list and compendium of national-level guidelines and protocols for selected countries based on the neoLENS policy review, as of February 2022.

The objective of this target product profile (TPP) is to describe key attributes—minimal and optimal targets—for microarray patch (MAP) delivery of COVID-19 vaccines. MAPs, also known as microneedle patches, consist of hundreds or thousands of microscopic projections that deliver dry vaccine or drug into the skin.The TPP describes key attributes for such a MAP for both LMIC and HIC markets. The document has been reviewed by a broad range of PATH staff with expertise in immunology, vaccine development, clinical trials, MAP technology, vaccine delivery, and vaccine manufacturing.

The COVID-19 Primer provides examples to planners, funders, and implementers looking to utilize digital health tools for pandemic and post-pandemic response. Created to guide digital investments in support of the COVID-19 vaccination response, the Primer showcases case studies that highlight the use of data and digital health tools to support immunization service delivery.

Virus hunter: Environmental surveillance and the polio endgame